Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
Zhikai ZhengJiongliang WangTianqing WuMinrui HeJuncheng WangYang-Xun PanJin-Bin ChenDandan HuLi XuYao-Jun ZhangMinshan ChenZhongguo ZhouPublished in: Journal of hepatocellular carcinoma (2023)
Compared with ETV, TDF was associated with a better prognosis, lower proportion of HBV reactivation, and better preservation of liver function in advanced HBV-HCC patients who underwent FOLFOX-HAIC, especially those who received ≥ 4 cycles.
Keyphrases
- hepatitis b virus
- liver failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute lymphoblastic leukemia
- prognostic factors
- type diabetes
- low dose
- metastatic colorectal cancer
- locally advanced
- patient reported outcomes
- antiretroviral therapy
- skeletal muscle
- insulin resistance
- weight loss